In this episode of Cancer Has No Borders, host Zach Randles-Friedman welcomes back Dr. Mark Lanasa, Senior Vice President and Chief Medical Officer at BeOne Medicines, for an in-depth conversation about the future of cancer drug development.

Dr. Lanasa breaks down what makes BeOne’s clinical pipeline stand out in an increasingly crowded solid tumor space—balancing deep scientific focus with broad diversification across targets, modalities, and tumor types. From EGFR and KRAS biology to combination therapies and global clinical trial execution, this episode explores how innovation, urgency, and patient access intersect in modern oncology.

The conversation also dives into the growing role of AI in R&D, the importance of internalized clinical development, why clinical trials are essential to advancing care, and what it means to build medicines with a truly global mission. At its core, this episode reinforces a simple truth: cancer has no borders—and neither should innovation.

🔬 Inside BeOne’s Oncology Pipeline

• How BeOne balances focus and diversification in solid tumor development
• Key disease areas: lung, GI, breast, gynecologic, and more
• Targeting core cancer drivers like EGFR and KRAS with multiple modalities

🩺 From Clinician to Chief Medical Officer

• Why Dr. Lanasa transitioned from treating patients to drug development
• Witnessing the shift from chemotherapy to targeted and immunotherapies
• How working on investigational medicines can impact patients worldwide

🌍 Global Access & Clinical Trials

• Why global patient access is central to BeOne’s mission
• The critical role of clinical trials in advancing cancer care
• Building diverse, international trial populations for better outcomes

🤖 AI, Automation & Speed in R&D

• How AI is accelerating protocol design, data analysis, and development timelines
• Where automation helps—and why human judgment still matters
• Reflections on how dramatically oncology innovation has changed in 20 years

🧬 Combination Therapy & Scientific Rigor

• Why most cancers require combination approaches
• Designing smarter trials for multi-drug regimens
• How BeOne’s in-portfolio combinations create unique advantages

🧪 Discovery, Innovation & What’s Next

• BeOne’s large-scale discovery engine and rigorous selection process
• Advancing first-in-class and best-in-class therapies
• Highlights from recent R&D milestones and investigational programs

❤️ Patients at the Center

• The sacrifice and courage of patients who join clinical trials
• Why meeting patients remains the most meaningful part of the work
• Reflecting on impact, teamwork, and long-term progress in oncology

Hosted on Acast. See acast.com/privacy for more information.